Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
AssigneeImmunoGen, Inc.
InventorsOlga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
Life of this patent
Estimating the term…
Abstract
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
Claims59
1-127. (canceled)
A method of treating cancer in a subject, comprising administering a therapeutically effective amount of an antibody that specifically binds human folate receptor 1 (FOLR1) to the subject, wherein the antibody comprises:
- (a) a heavy chain (HC) CDR1 comprising the amino acid sequence of GYTFTGYFMN (SEQ ID NO:132), a HC CDR2 comprising the amino acid sequence of RIHPYDGDTF (SEQ ID NO:131), and a HC CDR3 comprising the amino acid sequence of YDGSRAMDY (SEQ ID NO:3);
- and
- (b) a light chain (LC) CDR1 comprising the amino acid sequence of KASQSVSFAGTSLMH (SEQ ID NO:7);
- a LC CDR2 comprising the amino acid sequence of RASNLEA (SEQ ID NO:8), and a LC CDR3 comprising the amino acid sequence of QQSREYPYT (SEQ ID NO:9).
A method of treating cancer in a subject, comprising administering a therapeutically effective amount of an immunoconjugate having the formula (A)-(L)-(C) to the subject, wherein:
- (A) is an antibody or antigen binding fragment thereof that specifically binds human FOLR1;
- (L) is a linker;
- and
- (C) is a cytotoxic agent;
- wherein (L) links (A) to (C);
- and
- wherein the antibody or antigen binding fragment thereof comprises:
- (a) a HC CDR1 comprising the amino acid sequence of GYTFTGYFMN (SEQ ID NO:132), a HC CDR2 comprising the amino acid sequence of RIHPYDGDTF (SEQ ID NO:131), and a HC CDR3 comprising the amino acid sequence of YDGSRAMDY (SEQ ID NO:3);
- and
- (b) a LC CDR1 comprising the amino acid sequence of KASQSVSFAGTSLMH (SEQ ID NO:7), a LC CDR2 comprising the amino acid sequence of RASNLEA (SEQ ID NO:8) and a LC CDR3 comprising the amino acid sequence of QQSREYPYT (SEQ ID NO:9).
A method of treating cancer in a subject, comprising administering a therapeutically effective amount of an immunoconjugate having the formula (A)-(L)-(C) to the subject, wherein:
- (A) is an antibody or antigen binding fragment thereof that specifically binds human FOLR1;
- (L) is the linker N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (sulfo-SPDB);
- and
- (C) is the cytotoxic agent N(2′)-deacetyl-N(2′)-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (DM4);
- wherein (L) links (A) to (C);
- and
- wherein the antibody or antigen binding fragment thereof comprises:
- (a) a HC CDR1 comprising the amino acid sequence of GYTFTGYFMN (SEQ ID NO:132), a HC CDR2 comprising the amino acid sequence of RIHPYDGDTF (SEQ ID NO:131), and a HC CDR3 comprising the amino acid sequence of YDGSRAMDY (SEQ ID NO:3);
- and
- (b) a LC CDR1 comprising the amino acid sequence of KASQSVSFAGTSLMH (SEQ ID NO:7), a LC CDR2 comprising the amino acid sequence of RASNLEA (SEQ ID NO:8) and a LC CDR3 comprising the amino acid sequence of QQSREYPYT (SEQ ID NO:9).
Dependencies are inferred from the claim text.